Spectral Medical Inc. (EDT.TO)
Toronto · CAD · Healthcare · Diagnostics & Research
CA$0.99 (-1.00%) as of
Key statistics
- Market cap
- 290.62M
- Forward P/E
- 49.50
- EPS (TTM)
- -0.1200
- Dividend yield
- 0.00%
- 52-week range
- 0.9800 – 1.6000
- Beta
- 0.22
- Revenue (TTM)
- 2.57M
- Profit margin
- 0.00%
- Analyst target
- CA$3.15
- Volume
- 17.26k
About Spectral Medical Inc.
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Toronto, ON, Canada
- Employees
- 29
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.